Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Mexico
  4. Mexican Stock Exchange
  5. Genomma Lab Internacional, S.A.B. de C.V.
  6. News
  7. Summary
    LAB B   MX01LA010006

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.

(LAB B)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

GENOMMA LAB : Termination of XL-3 License Agreement

05/27/2011 | 07:15pm EDT

Mexico City, May 27th, 2011

GENOMMA LAB ANNOUNCES TERMINATION OF LICENSE AGREEMENT

G e n o m m a L a b I n t e r n a c i o n a l S . A . B . d e C . V . (BMV: LAB) (“Genomma Lab” or “the Company”) informs the investor public that, by agreement between the parties, has executed a termination agreement to the license agreement of the brand XL-3MR.

Such termination occurred since the parties were not able to reach a convenient agreement with respect to the final negotiations of the supply agreement; therefore Genomma Lab did not start any commercial activity of products under the license of this brand.

As a result of this event, the Company will recover $20 million pesos, which was the total amount paid for the license.

Genomma Lab anticipates that the termination of such license will not have an impact on the

2011 guidance provided by the Company.

It is worth mentioning that Genomma Lab has strongly gained market share during the last months in the anti-flu category with its brand Next, the brand with the highest increase of market share, which became one of the leaders in such category.Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low


© Publicnow 2011
All news about GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
07/13GENOMMA LAB INTERNACIONAL B DE C : 2Q-2021 Earnings Call Advisory
PU
04/28Genomma Lab Internacional, S.A.B. De C.V. Reports Earnings Results for the Fi..
CI
02/24Genomma Lab Internacional, S.A.B. De C.V. Reports Earnings Results for the Fo..
CI
02/24TRANCHE UPDATE ON GENOMMA LAB INTERN : LAB B)'s Equity Buyback Plan announced on..
CI
2020TRANCHE UPDATE ON GENOMMA LAB INTERN : LAB B)'s Equity Buyback Plan announced on..
CI
2020Genomma Lab Internacional, S.A.B. De C.V. Reports Earnings Results for the Th..
CI
2020Genomma Lab Internacional, S.A.B. de C.V. Informs Total Prepayment of Lab 18 ..
CI
2020Genomma Lab Internacional, S.A.B. De C.V. Reports Earnings Results for the Se..
CI
2020TRANCHE UPDATE ON GENOMMA LAB INTERN : LAB B)'s Equity Buyback Plan announced on..
CI
2020Genomma Lab Internacional SAB de CV Announces Earnings Results for the First ..
CI
More news
Financials
Sales 2021 14 552 M 726 M 726 M
Net income 2021 1 690 M 84,4 M 84,4 M
Net Debt 2021 3 421 M 171 M 171 M
P/E ratio 2021 12,9x
Yield 2021 2,84%
Capitalization 20 837 M 1 041 M 1 040 M
EV / Sales 2021 1,67x
EV / Sales 2022 1,44x
Nbr of Employees 1 310
Free-Float 70,9%
Chart GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Duration : Period :
Genomma Lab Internacional, S.A.B. de C.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 20,63 MXN
Average target price 26,03 MXN
Spread / Average Target 26,2%
EPS Revisions
Managers and Directors
Jorge Luis Brake Valderrama Chief Executive Officer
Antonio Zamora Galland Vice President-Administration & Finance
Rodrigo Alonso Herrera Aspra Chairman
Marco Sparvieri Chief Operating Officer & Executive Vice President
Juan Alonso Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.9.50%1 051
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246